Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(1.10) by 25.8 percent. This is a 31.43 percent decrease over losses of $(1.05) per share from the same period last year. The company reported quarterly sales of $21.36 million which missed the analyst consensus estimate of $28.11 million by 24.02 percent. This is a 4.20 percent decrease over sales of $22.30 million the same period last year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。